Acorda Therapeutics and Hangzhou Chance Pharmaceuticals join forces to introduce Parkinson's disease therapy in China; shares surge by 7%

Acorda Therapeutics (NASDAQ:ACOR) and Hangzhou Chance Pharmaceuticals announced a distribution and supply agreement for INBRIJA in China.
(ACOR) is up 7%.
The agreements include an up-front payment of $2.5M, a near-term milestone payment of up to $6M, $3M upon regulatory approval, up to $132.5M in sales milestones, and a fixed fee for each INBRIJA carton provided to Chance.
Chance intends to obtain regulatory clearance as soon as possible.
As of 2030, China is estimated to have about 5 million individuals with Parkinson’s disease, owing to its aging population.